International Journal of Colorectal Disease

, Volume 30, Issue 1, pp 105–110 | Cite as

Probiotics prevent Hirschsprung’s disease-associated enterocolitis: a prospective multicenter randomized controlled trial

  • Xiaolin Wang
  • Zhi Li
  • Zhilin Xu
  • Zhongrong Wang
  • Jiexiong FengEmail author
Original Article



Enterocolitis (EC) is the most common and serious postoperative complication of Hirschsprung’s disease (HD). Probiotics potentially play a protective role in maintaining intestinal mucosal integrity. Based on the beneficial effects of probiotics, we hypothesized that oral probiotics could decrease the incidence and severity of Hirschsprung’s disease-associated enterocolitis (HAEC).


We conducted a prospective, multicenter, randomized, and controlled trial to assess whether oral probiotics could decrease the incidence and severity of HAEC. HD patients were randomly assigned into the control group and probiotic-treated group. All children in probiotic-treated group were fed with probiotics per day for 4 weeks. In next 3 months, the incidence and severity of HAEC were analyzed. The peripheral blood T lymphocyte subsets and cytokines, including TNF-α, IFN-γ, IL-6, and IL-10, were analyzed by flow cytometry and enzyme immunoassay (EIA).


Compared with the control group, the incidence of HAEC in the probiotic-treated group was significantly diminished. The severity of EC was also remarkably decreased. Furthermore, probiotics balanced T lymphocyte subsets. Moreover, pro-inflammatory cytokines TNF-α, IFN-γ, and IL-6 were significantly decreased and anti-inflammatory cytokine IL-10 was notably increased in probiotic-treated group.


Probiotics not only significantly diminished the incidence but also decreased the severity of HAEC. Moreover, our study revealed that probiotics decreased pro-inflammatory cytokine and increased anti-inflammatory cytokine and furthermore balanced T lymphocytes (registered with, NCT number: NCT01934959).


Probiotics Hirschsprung’s disease-associated enterocolitis Prospective multicenter randomized controlled trial 



This study was funded by National Key Specialty ConstructionProgram (2013544) and National Natural Science Foundation of China (PI:Zhi Li;No:81400579).

Author contribution

Zhi Li and Xiaolin Wang wrote the manuscript. Jiexiong Feng designed the trial and revised the manuscript. Xiaolin Wang, Zhi Li, Zhilin Xu, Zhongrong Wang, and Jiexiong Feng coordinately conducted this trial.


  1. 1.
    Lilly DM, Stillwell RH (1965) Probiotics: growth promoting factors by microorganisms. Sci 147:747–748CrossRefGoogle Scholar
  2. 2.
    Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66:365–378PubMedCrossRefGoogle Scholar
  3. 3.
    Arnold C (2013) The pros and cons of probiotics. Lancet Infect Dis 13(7):571–572PubMedCrossRefGoogle Scholar
  4. 4.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32(2):147–152PubMedCrossRefGoogle Scholar
  5. 5.
    Geier MS, Butler RN, Howarth GS (2007) Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 115(1):1–11PubMedCrossRefGoogle Scholar
  6. 6.
    Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S (2007) Lactobacillus reuteri tablets suppress Helicobacter pylori infection—a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi 81(4):387–393PubMedCrossRefGoogle Scholar
  7. 7.
    Rafter J (2003) Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 17(5):849–859PubMedCrossRefGoogle Scholar
  8. 8.
    Barrons R, Tassone D (2008) Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 30(3):453–468PubMedCrossRefGoogle Scholar
  9. 9.
    Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 4:5PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Rosemary JY, Shari H (2003) Probiotic use in children. J Pediatr Health Care 17(6):277–283CrossRefGoogle Scholar
  11. 11.
    Sari FN, Dizdar EA, Oguz S, Erdeve O, Uras N, Dilmen U (2011) Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. Eur J Clin Nutr 65(4):434–439PubMedCrossRefGoogle Scholar
  12. 12.
    Barclay AR, Stenson B, Simpson JH, Weaver LT, Wilson DC (2007) Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 45(5):569–576PubMedCrossRefGoogle Scholar
  13. 13.
    Kliegman RM (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. J Pediatr 146(5):710PubMedCrossRefGoogle Scholar
  14. 14.
    Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatr 115(1):1–4Google Scholar
  15. 15.
    Austin KM (2012) The pathogenesis of Hirschsprung’s disease-associated enterocolitis. Semin Pediatr Surg 21(4):319–327PubMedCrossRefGoogle Scholar
  16. 16.
    Blanarova C, Galovicova A, Petrasova D (2009) Use of probiotics for prevention of radiation-induced diarrhea. Bratisl Lek Listy 110(2):98–104PubMedGoogle Scholar
  17. 17.
    Hackam DJ, Filler RM, Pearl RH (1998) Enterocolitis after the surgical treatment of Hirschsprung’s disease: risk factors and financial impact. J Pediatr Surg 33(6):830–833PubMedCrossRefGoogle Scholar
  18. 18.
    Murphy F, Puri P (2005) New insights into the pathogenesis of Hirschsprung’s associated enterocolitis. Pediatr Surg Int 21(10):773–779PubMedCrossRefGoogle Scholar
  19. 19.
    Elhalaby EA, Coran AG, Blane CE, Hirschl RB, Teitelbaum DH (1995) Enterocolitis associated with Hirschsprung’s disease: a clinical-radiological characterization based on 168 patients. J Pediatr Surg 30(1):76–83PubMedCrossRefGoogle Scholar
  20. 20.
    Caneiro P, Brereton R, Drake D et al (1992) Enterocolitis in Hirschsprung’s disease. Pediatr Surg Int 7:356–360Google Scholar
  21. 21.
    Teitelbaum DH, Cilley RE, Sherman NJ, Bliss D, Uitvlugt ND, Renaud EJ, Kirstioglu I, Bengston T, Coran AG (2000) A decade of experience with the primary pull-through for Hirschsprung disease in the newborn period: a multicenter analysis of outcomes. Ann Surg 232(3):372–380PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    De Filippo C, Pini-Prato A, Mattioli G, Avanzini S, Rapuzzi G, Cavalieri D, Di Paola M, Stefanini I, Ceccherini I, Mavilio D, Lionetti P, Jasonni V (2010) Genomics approach to the analysis of bacterial communities dynamics in Hirschsprung’s disease-associated enterocolitis: a pilot study. Pediatr Surg Int 26:465–471PubMedCrossRefGoogle Scholar
  23. 23.
    Wilson-Storey D, Scobie W (1989) Impaired gastrointestinal mucosal defense in Hirschsprung’s disease: a clue to the pathogenesis of enterocolitis? J Pediatr Surg 24:462–464PubMedCrossRefGoogle Scholar
  24. 24.
    Caniano DA, Teitelbaum DH, Qualman SJ, Shannon BT (1989) The piebald–lethal murine strain: investigation of the cause of early death. J Pediatr Surg 24:906–910PubMedCrossRefGoogle Scholar
  25. 25.
    Aslam A, Spicer RD, Corfield AP (1997) Children with Hirschsprung’s disease have an abnormal colonic mucus defensive barrier independent of the bowel innervation status. J Pediatr Surg 32:1206–1210PubMedCrossRefGoogle Scholar
  26. 26.
    Reis EA, Hagan JE, Ribeiro GS, Teixeira-Carvalho A, Martins-Filho OA, Montgomery RR, Shaw AC, Ko AI, Reis MG (2013) Cytokine response signatures in disease progression and development of severe clinical outcomes for leptospirosis. PLoS Negl Trop Dis 7(9):e2457PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Imamura A, Puri P, O’Briain DS, Reen DJ (1992) Mucosal immune defence mechanisms in enterocolitis complicating Hirschsprung’s disease. Gut 33(6):801–806PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Frykman PK, Short SS (2012) Hirschsprung-associated enterocolitis: prevention and therapy. Semin Pediatr Surg 21(4):328–335PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Xiaolin Wang
    • 1
  • Zhi Li
    • 1
  • Zhilin Xu
    • 2
  • Zhongrong Wang
    • 3
  • Jiexiong Feng
    • 1
    Email author
  1. 1.Department of Pediatric Surgery, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Pediatric SurgeryThe First Hospital Affiliated to Harbin Medical UniversityHarbinChina
  3. 3.Department of Pediatric SurgeryAnhui Provincial HospitalHefeiChina

Personalised recommendations